Table 1—

Baseline characteristics of randomized subjects

PlaceboFenofibrateCoQCombination
n20191619
Age (years)62.4 ± 8.864.8 ± 7.361.3 ± 4.163.0 ± 9.4
Male/female (n)14/613/613/313/6
BMI (kg/m2)30.7 ± 5.029.9 ± 5.630.1 ± 4.628.7 ± 3.4
Fasting glucose (mmol/l)7.2 ± 1.87.0 ± 1.17.6 ± 1.67.6 ± 2.2
GHb (%)6.5 ± 1.06.5 ± 0.96.6 ± 0.96.6 ± 0.8
Duration of type 2 diabetes (years)5.5 (4.1–7.5)4.5 (2.7–7.5)3.1 (1.8–5.4)3.0 (2.0–4.9)
Resting SBP (mmHg)130.5 ± 15.7131.0 ± 17.8136.8 ± 14.7132.8 ± 17.3
Resting DBP (mmHg)73.0 ± 11.873.3 ± 10.476.9 ± 10.074.1 ± 9.2
Total cholesterol (mmol/l)4.4 ± 1.24.6 ± 0.94.6 ± 0.94.6 ± 0.8
Triglycerides (mmol/l)1.6 ± 0.71.6 ± 1.01.7 ± 0.71.7 ± 0.8
HDL cholesterol (mmol/l)1.22 ± 0.271.29 ± 0.361.25 ± 0.251.35 ± 0.38
LDL cholesterol (mmol/l)2.5 ± 1.12.6 ± 0.72.6 ± 0.82.5 ± 0.7
Serum creatinine (umol/l)82 ± 1674 ± 1079 ± 1575 ± 15
History of ischemic heart disease15.015.812.510.5
LV hypertrophy20.026.36.310.5
LVDD: mild/moderate (n)16/417/215/116/3
Medications
    No antihyperglycemic medication25.042.143.826.3
    Metformin60.047.450.068.4
    Sulphonylurea50.042.137.521.1
    Nocturnal basal insulin5.010.56.30.0
    No antihypertensive medication35.063.250.063.2
    ACE inhibitor45.026.337.515.8
    Angiotensin receptor blocker15.010.56.35.3
    β-Adrenergic receptor blocker5.05.325.010.5
    Calcium channel blocker25.015.818.810.5
    Diuretic30.010.518.810.5
    Statin75.036.868.852.6
  • Data are means ± SD, percent, or geometric means (95% CI).